ID   K-562 KC/16
AC   CVCL_E4AH
SY   KC/16
RX   PubMed=7535698;
CC   Population: Caucasian.
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:6149; ITGAM.
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:6155; ITGB2.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 19-12-24; Last updated: 19-12-24; Version: 1
//
RX   PubMed=7535698; DOI=10.1002/eji.1830250302;
RA   Ortlepp S., Stephens P.E., Hogg N., Figdor C.G., Robinson M.K.;
RT   "Antibodies that activate beta 2 integrins can generate different
RT   ligand binding states.";
RL   Eur. J. Immunol. 25:637-643(1995).
//